Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Potential of longitudinal data from single site and multi-center clinical trials for AI-research

Prof. Dr. Hans-Christoph Becker from Stanford University, a long-standing user of mint Lesion™, shares his experience of using the software in this…

Home of excellence for cancer care innovation

In a multidisciplinary center that networks medical research, natural sciences, engineering sciences, computer science and business administration, in…

Royal Marsden London: Study shows prediction power of CT-based 2D and 3D texture analysis for liver metastases

2 minute(s)

In a retrospective study [1], a team from Royal Marsden in London and Sutton explored changes of CT texture analysis metrics in unresectable liver…